PCM
ADAP

Penserra Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Penserra Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,135
Closed -$16K – 1347
2021
Q3 		$16K Buy
3,135
+30
+1% +$135 ﹤0.01% 1279
2021
Q2 		$13K Buy
3,105
+5
+0.2% +$24 ﹤0.01% 1248
2021
Q1 		$16K Sell
3,100
-80
-3% -$458 ﹤0.01% 990
2020
Q4 		$17K Buy
+3,180
New +$17.3K ﹤0.01% 867

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Penserra Capital Management's ADAP Position: Q4 2021 in Review

Penserra Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 3,135 shares — an estimated $16K sold.

Penserra Capital Management first reported a position in ADAP in Q4 2020 and held it in 4 quarters. The position peaked at $17K in Q4 2020. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

  • Penserra Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 3,135 Adaptimmune Therapeutics shares in Q4 2021, an estimated $16K.
  • Penserra Capital Management first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Adaptimmune Therapeutics position peaked at $17K in Q4 2020.
  • 85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.